Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research • Sep 14, 2026

AtriCure CTO Sells 3,657 Shares

The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.

The Motley Fool • Sep 12, 2026

Do Options Traders Know Something About AtriCure Stock We Don't?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Zacks Investment Research • Sep 10, 2026

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Sep 9, 2026

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 27, 2026

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

Business Wire • Aug 25, 2026

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

Seeking Alpha • Aug 21, 2026

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

MarketBeat • Aug 12, 2026

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

The Motley Fool • Aug 7, 2026

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

The Motley Fool • Aug 7, 2026